Study of Placenta Angiogenic Function in Healthy Pregnancies at Term with Scheduled Cesarean Delivery

What this Trial Is About

This research aims to better understand how certain factors that control blood vessel growth, such as placenta growth factor PlGF and soluble FMS-like tyrosine kinase-1 sFlt-1, are expressed by trophoblastic cells in healthy placentas from normal pregnancies at term. The study also seeks to explore how these factors relate to placental function and differentiation, which are important for a healthy pregnancy. The study involves observing placentas from scheduled cesarean deliveries after 37 weeks of pregnancy. Researchers will examine the gene and protein levels of these angiogenic factors in the placental tissue. Additionally, they may expose these healthy placentas to various chemical compounds to study their effects on placental biology and to explore potential therapeutic targets for pregnancy complications like pre-eclampsia and intrauterine growth restriction. Participants will be involved through collection of placental tissue during cesarean delivery. Researchers will measure levels of placental angiogenic factors on the day of collection and follow up on specific protein levels the next day. The study includes laboratory tests and tissue analysis to assess placental function and angiogenic factor expression, aiming to improve understanding of placental health and its disorders during pregnancy.

ANgiogenic Function at NOrmal TErm on Placenta